Kidney Failure Treatment (ESKD) — Cost, Top Hospitals & Success Rates | MyMedicPlus

End-stage kidney disease (ESKD), also called kidney failure or stage G5 chronic kidney disease (CKD), is defined by a glomerular filtration rate (GFR) below 15 mL/min/1.73 m² accompanied by uraemic symptoms or complications requiring active renal replacement therapy (RRT). Globally, over 3.9 million people receive some form of RRT, and incidence is rising by 5–7% annually, driven largely by the epidemics of type 2 diabetes, hypertension, and obesity.

Without treatment, ESKD is incompatible with survival beyond days to weeks due to hyperkalaemia, pulmonary oedema, metabolic acidosis, and uraemic encephalopathy. However, modern RRT options allow patients to live for decades with acceptable quality of life, and kidney transplantation can restore near-normal kidney function in eligible recipients.

The four principal treatment modalities for ESKD are:

1. Haemodialysis (HD) — blood is filtered through an artificial kidney (dialyser) using a dialysis machine, typically 3 times weekly in-centre or with greater flexibility at home
2. Peritoneal Dialysis (PD) — the patient's own peritoneal membrane filters waste products using dialysis fluid instilled into the abdominal cavity
3. Kidney Transplantation — a functioning kidney from a living or deceased donor is surgically implanted, with immunosuppression to prevent rejection
4. Conservative Kidney Management (CKM) — symptom-focused palliative care without dialysis, for patients (typically elderly or frail) for whom the burdens of dialysis outweigh the benefits

The choice between modalities should be made through shared decision-making between the patient, their family, and a multidisciplinary kidney team including a nephrologist, transplant surgeon (if applicable), renal dietitian, CKD nurse specialist, social worker, and — for CKM — palliative care team. There is no universally 'best' modality; the optimal choice depends on medical eligibility, patient preferences, home circumstances, and lifestyle goals.

Kidney failure requiring RRT arises from a wide spectrum of underlying causes, which may influence the choice of RRT modality and transplant outcomes.

Leading Causes of ESKD (Global)

• Diabetic Kidney Disease (DKD): The leading cause worldwide, responsible for 35–45% of ESKD in high-income countries. Type 2 diabetes-related ESKD has the highest attributable proportion in South and East Asian populations. The advent of SGLT2 inhibitors has begun to reduce incidence rates in treated populations.
• Hypertensive Nephrosclerosis: Responsible for 25–30% of ESKD. Often overlaps with diabetic nephropathy. Particularly prevalent in patients of African descent.
• IgA Nephropathy: The most common primary glomerulonephritis worldwide; characterised by mesangial IgA deposition, episodic gross haematuria, and proteinuria. Approximately 30–40% of IgA nephropathy patients progress to ESKD over 20 years. New therapies (sparsentan, targeted-release budesonide) have recently improved outcomes.
• Focal Segmental Glomerulosclerosis (FSGS): Primary and secondary forms; associated with heavy proteinuria and rapid progression. High recurrence rate after transplant (25–50% in primary FSGS).
• Polycystic Kidney Disease (ADPKD and ARPKD): Autosomal dominant PKD is the most common inherited kidney disease, accounting for 5–10% of ESKD. Tolvaptan (a vasopressin-2 receptor antagonist) slows cyst growth and GFR decline in patients at risk of rapid progression.
• Lupus Nephritis (LN): Proliferative lupus nephritis (Class III–IV) carries ESKD risk of 10–25% over 10 years. Belimumab and voclosporin have improved remission rates.
• Recurrent Urinary Tract Infections and Reflux Nephropathy: A preventable cause in children; upper UTI-related scarring is a leading cause of childhood ESKD.

When is RRT Initiated?

The decision to initiate RRT is clinical, not purely number-based. Absolute indications include: severe hyperkalaemia (K⁺ >6.5 mmol/L refractory to medical management), pulmonary oedema unresponsive to diuretics, metabolic acidosis (pH <7.1) refractory to bicarbonate, uraemic pericarditis, uraemic encephalopathy or seizures, and bleeding diathesis from platelet dysfunction. Elective initiation occurs when GFR falls to 5–10 mL/min/1.73 m² with symptomatic uraemia (severe fatigue, nausea, cachexia, pruritus). The IDEAL trial (2010) demonstrated no survival benefit from early vs late (symptom-guided) HD initiation, supporting the current preference for symptom-guided start.

Modality selection is one of the most important decisions in nephrology, with long-term implications for quality of life, survival, and healthcare costs. KDIGO recommends a structured education process that provides patients with unbiased information about all modalities before a preference is expressed.

Kidney Transplant — Best Overall Outcomes, Not Available to All

Kidney transplantation provides the longest survival and best quality of life of all RRT modalities. Living-donor transplant in a healthy 45-year-old offers expected kidney graft survival of over 20 years and patient survival exceeding 10 years beyond matched dialysis counterparts. Pre-emptive transplantation (before dialysis initiation, GFR 6–10 mL/min/1.73 m²) from a living donor is associated with the best graft and patient survival outcomes and avoids dialysis entirely. However, transplant is not suitable for: active malignancy within 2–5 years, severe heart disease with expected survival <5 years, active infection, untreated psychiatric illness with inability to adhere to immunosuppression, or lack of social support for post-transplant medication management.

Haemodialysis — Most Common Globally

HD is the most widely available RRT globally. Standard in-centre HD suits patients who prefer clinic supervision, cannot manage self-care at home, lack home support, or have peritoneal membrane failure. Home HD programmes offer flexibility and improved outcomes but require motivated patients with suitable home environments and a trained support person.

Peritoneal Dialysis — Best for Home-Based Start

PD is preferred for patients who value independence and wish to avoid the rigid schedule of in-centre HD. PD is particularly favoured for young working patients, diabetic patients with labile haemodynamics (as PD provides gentler continuous fluid removal), patients in remote areas, and those awaiting kidney transplant who wish to avoid dialysis-centre attendance. Relative contraindications include prior major abdominal surgeries, active inflammatory bowel disease, severe diaphragmatic defects (risk of pleural hydrothorax), and severe physical limitations that preclude self-catheter care.

Conservative Kidney Management — For Elderly/Frail Patients

CKM without dialysis is a legitimate and evidence-supported choice for elderly patients (typically >75 years) with significant comorbidities (severe cardiac disease, dementia, frailty) where survival benefit of dialysis over comprehensive CKM is uncertain or marginal. Studies have shown that frail ESKD patients aged >75 have comparable or only modestly inferior median survival on CKM vs dialysis (6–24 months), with significantly better quality of life and avoidance of haemodialysis-related burdens (3-day-per-week travel, access complications, inter-dialytic fatigue).

Each RRT modality has specific technical features, schedules, access requirements, and clinical management protocols.

Haemodialysis (HD)

Standard In-Centre HD: The patient attends a dialysis centre 3 times per week for sessions of 3.5–5 hours. Blood is removed via an arteriovenous (AV) fistula (the gold-standard vascular access, created surgically 3–6 months before HD start), AV graft, or central venous catheter (CVC, used as a bridge or when fistula is not feasible). Blood passes through a dialyser membrane where uraemic toxins and excess fluid are removed by diffusion and ultrafiltration. Dialysis adequacy is measured by Kt/V (urea clearance index, target ≥1.4 per session) or urea reduction ratio (>65%).

Home HD (HHD): Allows HD at home, typically performed 5–6 times per week for shorter sessions (2.5 hours, short daily HD) or 3 nights per week for 6–8 hours (nocturnal HD). Nocturnal HD provides superior clearance of middle molecules and phosphate, better blood pressure control, and improved quality of life. NxStage System One and Fresenius 2008K@home are commonly used HHD machines. HHD requires thorough patient and carer training (typically 4–6 weeks), home assessment, and ongoing remote monitoring support.

Peritoneal Dialysis (PD)

Continuous Ambulatory Peritoneal Dialysis (CAPD): 3–4 manual bag exchanges per day, each lasting 30 minutes (including drain, fill, dwell). Glucose-based dialysis fluid (1.5%, 2.5%, or 4.25% dextrose) or icodextrin (for overnight long dwell) is instilled via a permanent silicone catheter (Tenckhoff catheter) inserted into the peritoneal cavity. CAPD provides continuous, gentle dialysis 24 hours per day, 7 days per week, mimicking residual kidney function more closely than HD.

Automated Peritoneal Dialysis (APD): A cycler machine performs multiple rapid exchanges overnight (typically 9–10 hours, 4–6 exchanges), leaving the patient free during the day. APD suits working patients and those who prefer daytime freedom. The most common complication of PD is peritonitis (infection of the peritoneal space, approximately 0.3–0.5 episodes per patient-year) — presenting with cloudy effluent, abdominal pain, and fever, managed with intraperitoneal antibiotics. PD technique failure (peritoneal membrane exhaustion or recurrent peritonitis) typically occurs after 5–7 years, requiring transfer to HD or transplant.

Kidney Transplantation

Living Donor Transplant: A kidney is donated by a living relative (emotionally related or altruistic unrelated donor). Living donor transplants are planned electively, offer better HLA matching opportunities, and provide immediate graft function. Laparoscopic donor nephrectomy minimises donor morbidity. Pre-operative evaluation of the donor includes GFR assessment, imaging (CT angiogram), cardiovascular risk stratification, and psychological assessment. Kidney Paired Donation (KPD) or chain exchange programmes allow incompatible live donor pairs to be matched with compatible recipients.

Deceased Donor Transplant: Kidneys from brain-dead (DBD) or donation after circulatory death (DCD) donors. Cold ischaemia time (<18–24 hours ideal) affects graft outcomes. Allocation is based on HLA matching, time on waiting list, geographical proximity, and medical urgency. Standard criteria donor (SCD) and expanded criteria donor (ECD, typically older donors or with some comorbidity) kidneys carry different outcome profiles; ECD kidneys may be offered to older recipients after informed discussion.

Post-Transplant Immunosuppression: Standard triple therapy includes a calcineurin inhibitor (tacrolimus, target trough 5–10 ng/mL in the first year), an antiproliferative agent (mycophenolate mofetil 1,500–2,000 mg/day or sodium mycophenolate), and a corticosteroid (prednisolone 5 mg/day long-term). Rejection episodes — acute T-cell-mediated rejection or antibody-mediated rejection — are managed with pulse methylprednisolone, plasmapheresis, and rituximab.

Conservative Kidney Management (CKM)

CKM is an active, structured, multidisciplinary approach focusing on: symptom management (pruritus managed with gabapentin or difelikefalin; nausea with metoclopramide or ondansetron; breathlessness with low-dose opiates; pain with non-opioid analgesics avoiding NSAIDs), optimal medical management to preserve residual kidney function, psychosocial support, advance care planning, and timely transition to hospice or palliative care when appropriate. CKM does not mean 'doing nothing' — it means choosing maximal quality of life over quantity of life.

All RRT modalities extend life and improve quality of life compared with no treatment in ESKD. Specific outcome advantages differ by modality.

Survival Outcomes

• Kidney transplant offers the best survival: a 40-year-old receiving a living-donor kidney can expect median graft survival of 18–22 years and patient survival that exceeds dialysis counterparts by 10–15 years (US Renal Data System). Younger patients with no comorbidity and HLA-matched living donors have 10-year patient survival rates exceeding 90%.
• Pre-emptive living-donor transplant reduces graft failure risk by 25% compared with post-dialysis transplant, eliminates dialysis-associated morbidities, and is the recommended pathway for eligible patients with available living donors.
• Haemodialysis median patient survival from dialysis initiation ranges from 4–10 years depending on age and comorbidity. Annual mortality rates are 15–20% in the general dialysis population, though young diabetic-free patients may survive 20+ years on HD.
• Peritoneal dialysis provides comparable survival to HD in the first 1–3 years, with some evidence of better early outcomes (particularly in patients with preserved residual kidney function) and worse long-term survival due to technique failure and peritoneal membrane deterioration. Hybrid approaches (PD transitioning to HD) are common and reasonable.

Quality of Life

Home-based therapies (home HD and PD) consistently demonstrate superior patient-reported quality of life, greater employment retention, and better sleep quality compared with in-centre HD, due to reduced travel burden and greater schedule autonomy. Kidney transplant recipients report the highest quality of life among all RRT modalities — including return to work rates exceeding 60% within 2 years of transplant.

Residual Kidney Function

Preservation of residual kidney function (RKF) is associated with reduced cardiovascular mortality and better quality of life in dialysis patients. PD is superior to HD in preserving RKF in the first 2 years; home HD and less frequent in-centre HD sessions may also be more protective than standard 3x/week HD.

Each RRT modality carries specific complication profiles that must be discussed with patients during modality education.

Haemodialysis Complications

• Vascular Access Complications: AV fistula thrombosis (15–25% per year), stenosis (requires balloon angioplasty or surgical revision), and infection. Tunnelled CVC-related bloodstream infections (incidence 1–3 per 1,000 catheter-days) carry 20% mortality if untreated — CVC should be used as short-term bridge only.
• Haemodynamic Instability: Intradialytic hypotension (IDH) occurs in 20–30% of sessions, particularly in elderly patients and those with cardiac disease, causing dizziness, cramps, and reduced dialysis adequacy. Cooled dialysate, blood volume monitoring, and midodrine are management strategies.
• Inter-Dialytic Symptoms: Post-dialysis fatigue ('washed out feeling'), restless legs syndrome, and cramps significantly impact quality of life. Muscle cramps affect 30–40% of HD patients.
• Cardiovascular Disease: Leading cause of death in dialysis patients (50–60% of deaths). Dialysis-dependent patients are at 10–100 times the cardiovascular event rate of the general population. Left ventricular hypertrophy is nearly universal by ESKD onset.

Peritoneal Dialysis Complications

• Peritonitis: The most serious PD complication. Staphylococcus aureus and S. epidermidis (from exit-site contamination) are most common; gram-negative organisms indicate bowel contamination. Fungal peritonitis (Candida) requires immediate PD catheter removal. Recurrent peritonitis is the leading cause of technique failure.
• Exit-Site and Tunnel Infection: Managed with topical mupirocin prophylaxis and oral antibiotics; uncontrolled infection may necessitate catheter removal.
• Encapsulating Peritoneal Sclerosis (EPS): A rare but life-threatening fibrosclerosing complication occurring after 5–8 years of PD in susceptible patients, causing bowel obstruction. Tamoxifen and surgical enterolysis are treatment options.
• Ultrafiltration Failure: Progressive loss of peritoneal water transport capacity, typically after 5–7 years, requiring transition to HD or transplant.

Transplant Complications

• Rejection: Acute T-cell-mediated rejection (5–10% in the first year with modern immunosuppression), antibody-mediated rejection (AMR, 5–8%), and chronic allograft nephropathy (leading cause of late graft loss).
• Infection: Immunosuppression increases susceptibility to CMV, BK virus nephropathy, Pneumocystis jirovecii pneumonia (PJP), and opportunistic fungal infections. Prophylaxis with valganciclovir (CMV), trimethoprim-sulfamethoxazole (PJP), and antifungals is standard in the first 3–6 months.
• Malignancy: Transplant recipients have a 3–4 times higher cancer risk than the general population. Skin cancer (SCC), lymphoma (PTLD), and Kaposi sarcoma are most common. Annual skin surveillance and sun protection are mandatory.
• Calcineurin Inhibitor Nephrotoxicity: Tacrolimus and ciclosporin cause chronic nephrotoxicity, contributing to graft loss over decades. Dose minimisation and mTOR inhibitor-sparing protocols are used in some centres.

Patients on RRT require lifelong structured multidisciplinary follow-up. The frequency and content of monitoring differs substantially by modality.

Haemodialysis Monitoring

Monthly blood tests at each HD unit: haemoglobin, serum albumin, ferritin and transferrin saturation (TSAT), potassium, bicarbonate, calcium, phosphate, PTH, and Kt/V adequacy measurement. Quarterly: lipid profile, HbA1c in diabetics. Annual: echocardiogram, AV access Doppler assessment, DEXA scan if steroid use, ophthalmology for diabetics.

Peritoneal Dialysis Monitoring

Monthly: PD effluent cell count (peritonitis surveillance), blood tests (as above), blood pressure and fluid status assessment, Kt/V and creatinine clearance (weekly peritoneal dialysis dose). Quarterly: peritoneal equilibration test (PET) — assessment of peritoneal membrane transport characteristics to optimise PD regimen. Annual: CT of abdomen if long-term PD patient (EPS surveillance).

Post-Transplant Monitoring

Intensive monitoring in the first 3 months (twice-weekly clinic visits) includes: serum creatinine and eGFR, tacrolimus trough levels (target 8–12 ng/mL in month 1, 5–8 ng/mL in months 2–6), CMV and BK viral loads (monthly for 6 months), FBC (myelosuppression risk with mycophenolate), liver function, fasting glucose (NODAT — new-onset diabetes after transplant, occurs in 15–20% of recipients), and blood pressure. Graft biopsy is performed for unexplained creatinine rise >25% from baseline.

Dietary Management on Dialysis

Dietary restrictions are significant and modality-specific. HD patients restrict: potassium (<2 g/day — avoid bananas, oranges, tomatoes, potatoes), phosphate (<1,000–1,200 mg/day — avoid dairy, nuts, processed meats, cola drinks), sodium (<2 g/day — restrict inter-dialytic weight gain to <5% dry body weight), and fluid (typically <1.5 L/day inclusive of all beverages and fluid-containing foods). PD patients typically have fewer potassium and fluid restrictions than HD patients due to daily continuous clearance. Transplant recipients face fewer dietary restrictions — low-sodium diet and avoidance of grapefruit (inhibits tacrolimus metabolism) are the main dietary considerations.

ESKD treatment is among the most expensive chronic disease management globally, though costs vary enormously by modality and country.

Haemodialysis Costs

In India, in-centre HD costs INR 8,000–20,000 per month at government hospitals with subsidy schemes, and INR 30,000–80,000 per month at private dialysis centres (accounting for 3 sessions per week). The Pradhan Mantri National Dialysis Programme (PMNDP) provides free HD at government facilities for PMJAY beneficiaries. In the US, the annual cost of in-centre HD is approximately USD 80,000–100,000 per year, covered by Medicare ESKD benefit (available regardless of age). In the UK, NHS funds all HD at no patient cost.

Peritoneal Dialysis Costs

PD is generally less expensive than in-centre HD due to lower infrastructure and staffing costs. Monthly dialysate and consumable costs in India range from INR 20,000–40,000; in the US, approximately USD 3,000–4,000/month (USD 36,000–48,000/year). PD is particularly cost-effective for healthcare systems and may be the preferred modality from a health economics perspective for early-incident ESKD patients.

Kidney Transplant Costs

Kidney transplantation has a high upfront cost but is highly cost-effective long-term as it eliminates ongoing dialysis costs. In India, living-donor kidney transplant at a top private hospital costs INR 8–18 lakhs (USD 10,000–22,000) for the surgery, including donor evaluation and 1-month post-operative care. Annual post-transplant immunosuppression costs (tacrolimus, mycophenolate, prednisolone) range from INR 30,000–80,000 per year on generics. In the US, transplant surgery costs USD 150,000–350,000, funded by Medicare and most private insurers. The PMJAY scheme in India covers kidney transplantation at empanelled hospitals for eligible beneficiaries.

Total Cost-of-Illness Perspective

Over a 10-year horizon, kidney transplant is consistently the most cost-effective ESKD treatment option in health economic analyses from the US, UK, Australia, and India. A successful living-donor transplant saves an estimated USD 250,000–500,000 in dialysis costs over 10 years in high-income countries, while providing superior quality-adjusted life years (QALYs).

The field of ESKD treatment is evolving rapidly, with several exciting technologies and strategies either recently approved or in advanced clinical development.

Wearable and Implantable Artificial Kidneys

The Wearable Artificial Kidney (WAK) project (University of Washington, Vanderbilt University) aims to create a portable, battery-powered haemodialysis device worn around the waist, enabling continuous ambulatory dialysis 24 hours per day. Phase II trials have demonstrated feasibility and improved phosphate clearance. Commercial release is anticipated in the late 2020s. The Implantable Artificial Kidney (IAK) project uses silicon nanopore membranes and bioreactor technology housing human tubular cells to replicate not just filtration but tubular reabsorption — moving towards a true bioartificial kidney. Pre-clinical trials are ongoing.

Xenotransplantation

Genetically modified pig-to-human kidney transplantation has achieved major milestones in 2024–2026, with reports of multi-week graft survival in brain-dead human recipients using 10-gene edited pigs (removal of porcine xenoantigens, insertion of human immune regulatory genes). If successful in living recipients, xenotransplantation could resolve the critical shortage of deceased donor kidneys. Regulatory approval is anticipated to require several more years of clinical data.

Renal Stem Cell and Organoid Research

Kidney organoids derived from induced pluripotent stem cells (iPSCs) have been grown in laboratory settings and are advancing towards vascularised mini-kidneys for drug testing and — speculatively — future transplant. Practical clinical application remains 10–20 years away.

High-Volume Haemodiafiltration (HDF)

Online haemodiafiltration combines diffusion (HD) with convection (removal of larger 'middle molecule' uraemic toxins) and has demonstrated 30–35% reduction in all-cause mortality compared with standard HD in the ESHOL and CONTRAST trials. High-volume HDF (convection volume >23 L per session) is available at specialist centres and increasingly considered the standard of care for in-centre dialysis in Europe.

Immunosuppression-Free Transplantation (Tolerance Induction)

Protocols combining donor bone marrow infusion with kidney transplant at the time of surgery have successfully induced operational tolerance (a state where the graft is accepted without ongoing immunosuppression) in approximately 30–40% of recipients in trials at Stanford and Massachusetts General Hospital. Complete withdrawal of immunosuppression in tolerant recipients eliminates infection, malignancy, and nephrotoxicity risks. This remains an experimental approach restricted to selected living-donor pairs.